Addressing the Issue of Tetrodotoxin Targeting
AbstractThis review is devoted to the medical application of tetrodotoxin (TTX), a potent non-protein specific blocker of voltage-gated sodium (NaV) channels. The selectivity of action, lack of affinity with the heart muscle NaV channels, and the inability to penetrate the blood–brain barrier make this toxin an attractive candidate for anesthetic and analgesic drug design. The efficacy of TTX was shown in neuropathic, acute and inflammatory pain models. The main emphasis of the review is on studies focused on the improvement of TTX efficacy and safety in conjunction with additional substances and drug delivery systems. A significant improvement in the effectiveness of the toxin was demonstrated when used in tandem with vasoconstrictors, local anesthetics and chemical permeation enhancers, with the best results obtained with the encapsulation of TTX in microparticles and liposomes conjugated to gold nanorods. View Full-Text
Share & Cite This Article
Melnikova, D.I.; Khotimchenko, Y.S.; Magarlamov, T.Y. Addressing the Issue of Tetrodotoxin Targeting. Mar. Drugs 2018, 16, 352.
Melnikova DI, Khotimchenko YS, Magarlamov TY. Addressing the Issue of Tetrodotoxin Targeting. Marine Drugs. 2018; 16(10):352.Chicago/Turabian Style
Melnikova, Daria I.; Khotimchenko, Yuri S.; Magarlamov, Timur Y. 2018. "Addressing the Issue of Tetrodotoxin Targeting." Mar. Drugs 16, no. 10: 352.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.